Stockwatch: The TIGER That Came To Lilly
Executive Summary
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
You may also be interested in...
Stockwatch: Regeneron Failure Could Hurt Rivals More
A Friday morning clinical trial result at Regeneron had implications across a large number of companies marketing and developing ant-VEGF and anti-PDGF drugs including Ophthotech, Allergan, Roche and Novartis.
Stockwatch: Lilly And GW Move Goalposts
There were few bright spots last week in life sciences, with the NASDAQ Biotech Index finishing down by 4% as it continued, uncharacteristically, to underperform the broad S&P 500 index. The handful of positive announcements from the industry actually look very fragile on closer inspection, perhaps marking new lows for an industry where the integrity of clinical trial announcements and investment bank analysis can no longer be believed in.
Stockwatch: Oscillating fortunes
For some companies reporting their second-quarter earnings, last week was one of fluctuating fortunes. What the market gave to their share prices on one day it took away the next, and running through earnings season was that consistently big subtraction – the effect of foreign currency translations – and the concern that it may yet accelerate.